TremblaySNigroVWeinbergJWoodleESAllowayRR.A steady-state head-to-head pharmacokinetic comparison of all FK-506 (tacrolimus) formulations (ASTCOFF): an open-label, prospective, randomized, two-arm, three-period crossover study. Am J Transplant. 2017;17:432-442. doi:10.1111/ajt.13935
3.
RostaingLBunnapradistSGrinyóJMet al. Novel once-daily extended-release tacrolimus versus twice-daily tacrolimus in de novo kidney transplant recipients: two-year results of phase 3, double-blind, randomized trial. Am J Kidney Dis. 2016;67:648-659. doi:10.1053/j.ajkd.2015.10.024
4.
BrennanDWest-ThielkePStevensD.Pharmacokinetics of once-daily Envarsus XR in diabetic vs. non-diabetic kidney transplant recipients: a pooled subgroup analysis. Abstract presented at: ASN Kidney Week; November 15-20, 2016; Chicago, IL.
5.
StrattaPQuagliaMCenaTet al. The interactions of age, sex, body mass index, genetics, and steroid weight-based doses on tacrolimus dosing requirement after adult kidney transplantation. Eur J Clin Pharmacol. 2012;68:671-680.
LangoneASteinbergSMGedalyRet al. Switching study of kidney transplant patients with tremor to LCP-tacro (STRATO): an open-label, multicenter, prospective phase 3b study. Clin Transplant. 2015;29:796-805. doi:10.1111/ctr.12581
